<DOC>
	<DOCNO>NCT01854255</DOCNO>
	<brief_summary>A prospective series patient recurrent gastric cancer treat three cycle chemotherapy ( doxorubicin cisplatin ) instill abdominal cavity form aerosol pressure via laparoscopy . The efficacy treatment assess computed tomography , tumor marker study , survival . Also , safety procedure assess .</brief_summary>
	<brief_title>Intraperitoneal Aerosol Chemotherapy Gastric Cancer</brief_title>
	<detailed_description>Objectives : To evaluate safety efficacy term clinical benefit rate ( CBR ) PIPAC peritoneal carcinomatosis ( PC ) gastric cancer ( GC ) Study design : Single center , open label , non-randomized , single-arm , repeat single dose study explore efficacy , safety , CBR doxorubicin cisplatin give pressurized intraperitoneal aerosol chemotherapy ( PIPAC ) patient advanced gastric cancer peritoneal carcinomatosis . Target subject population : Patients GC PC disease progression least one line previous i.v . chemotherapy . Investigational product , dosage mode administration Doxorubicin 1.5 mg/m2 body surface 50 ml NaCl 0,9 % Cisplatin 7.5 mg/m2 50 ml NaCl 0,9 % q 4-6 week , apply intraperitoneally PIPAC . Duration treatment : 3 single dos 6 week interval , duration treatment 18 week Outcome variable : 1.1 Primary outcome variable • Clinical Benefit Rate ( CBR ) accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion ( version 1.1 ) 3 cycle PIPAC cisplatin doxorubicin . 1.2 Secondary outcome variable - The observed survival ( OS ) - The median time progression ( TTP ) accord RECIST criterion three cycle PIPAC cisplatin doxorubicin - The Peritoneal Carcinomatosis Index ( PCI ) therapy - The degree histological regression assess pathological review - Apoptosis assess immunohistochemical analysis - The difference ascites volume first , second , third PIPAC application 1.3 Patient report outcome ( PROs ) - European Organization Research Treatment Cancer ( EORTC ) quality life questionnaire ( QLQ-C30 , German version ) 1.4 Safety - Safety tolerability assess collection adverse event , accord Common Terminology Criteria Adverse Events ( CTCAE ) include physical examination result , laboratory assessment ( chemistry hematology ) . 1.5 Biological monitoring • Basic research investigate expression gene associate drug resistance .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>age 18 year write , informed consent presence peritoneal carcinomatosis language barrier parenchymal metastasis unability undergo laparoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gastric</keyword>
	<keyword>Cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Intraperitoneal</keyword>
</DOC>